We recently found that prednisone, the current standard treatment for Duchenne muscular dystrophy (DMD), improves thrashing rate, muscle strength, and mitochondrial respiration in
dys-1 worms (Hewitt, et al., 2018). Given that prednisone is an anti-inflammatory agent and that C. elegans largely lack a mammalian inflammatory system, we were interested in better understanding how prednisone works. Since excitation contraction coupling is required for normal muscle function, we tested prednisone's effect on the
dys-1's levamisole resistance and surprisingly found little improvement. This suggests that prednisone is not improving the altered calcium dynamics in
dys-1. Since
dys-1 animals are fainters, another phenotype associated with altered calcium dynamics, we tested if
dys-1 animals are halothane hypersensitive. Unsurprisingly, we found that
dys-1 animals are hypersensitive to halothane and that this hypersensitivity is not reversed by prednisone. Together, these results raise the question of if
dys-1 halothane sensitivity is related to
unc-68 malignant hypothermia variant's halothane sensitivity. These results also suggest that future drug discovery studies should target the excitation contraction coupling defect in
dys-1. Finding that prednisone did not substantially improve calcium handling, we hypothesized that prednisone improved muscle health by increasing mitochondrial biogenesis and/or altering mitochondrial function during the major expansion of mitochondria in the later larval stages. Surprisingly, we found treatment of fully developed adult
dys-1 worms with prednisone both increased thrashing rates and delayed declines in thrashing with age compared to untreated controls. This result suggests a more detailed analysis of prednisone's acute effect on mitochondrial function is required, which could lead to discovery of compounds that do not have the same undesired side effects as prednisone.